[ Search ] [ Legislation ]
[ Home ] [ Back ] [ Bottom ]
91_HB4389
LRB9110009RCpr
1 AN ACT to amend the Illinois Controlled Substances Act by
2 changing Sections 204, 206, 208, 210, and 214 and adding
3 Section 217.
4 Be it enacted by the People of the State of Illinois,
5 represented in the General Assembly:
6 Section 5. The Illinois Controlled Substances Act is
7 amended by changing Sections 204, 206, 208, 210, and 214 and
8 adding Section 217 as follows:
9 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
10 Sec. 204. (a) The controlled substances listed in this
11 Section are included in Schedule I.
12 (b) Unless specifically excepted or unless listed in
13 another schedule, any of the following opiates, including
14 their isomers, esters, ethers, salts, and salts of isomers,
15 esters, and ethers, whenever the existence of such isomers,
16 esters, ethers and salts is possible within the specific
17 chemical designation:
18 (1) Acetylmethadol;
19 (1.1) Acetyl-alpha-methylfentanyl
20 (N-[1-(1-methyl-2-phenethyl)-
21 4-piperidinyl]-N-phenylacetamide);
22 (2) Allylprodine;
23 (3) Alphacetylmethadol, except
24 levo-alphacetylmethadol (also known as levo-alpha-
25 acetylmethadol, levomethadyl acetate, or LAAM);
26 (4) Alphameprodine;
27 (5) Alphamethadol;
28 (6) Alpha-methylfentanyl
29 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
30 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
31 propanilido) piperidine;
-2- LRB9110009RCpr
1 (6.1) Alpha-methylthiofentanyl
2 (N-[1-methyl-2-(2-thienyl)ethyl-
3 4-piperidinyl]-N-phenylpropanamide);
4 (7) 1-methyl-4-phenyl-4-proprionoxypiperidine
5 (MPPP);
6 (7.1) PEPAP
7 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
8 (8) Benzethidine;
9 (9) Betacetylmethadol;
10 (9.1) Beta-hydroxyfentanyl
11 (N-[1-(2-hydroxy-2-phenethyl)-
12 4-piperidinyl]-N-phenylpropanamide);
13 (10) Betameprodine;
14 (11) Betamethadol;
15 (12) Betaprodine;
16 (13) Clonitazene;
17 (14) Dextromoramide;
18 (15) Diampromide;
19 (16) Diethylthiambutene;
20 (17) Difenoxin;
21 (18) Dimenoxadol;
22 (19) Dimepheptanol;
23 (20) Dimethylthiambutene;
24 (21) Dioxaphetylbutyrate;
25 (22) Dipipanone;
26 (23) Ethylmethylthiambutene;
27 (24) Etonitazene;
28 (25) Etoxeridine;
29 (26) Furethidine;
30 (27) Hydroxpethidine;
31 (28) Ketobemidone;
32 (29) Levomoramide;
33 (30) Levophenacylmorphan;
34 (31) 3-Methylfentanyl
-3- LRB9110009RCpr
1 (N-[3-methyl-1-(2-phenylethyl)-
2 4-piperidyl]-N-phenylpropanamide);
3 (31.1) 3-Methylthiofentanyl
4 (N-[(3-methyl-1-(2-thienyl)ethyl-
5 4-piperidinyl]-N-phenylpropanamide);
6 (32) Morpheridine;
7 (33) Noracymethadol;
8 (34) Norlevorphanol;
9 (35) Normethadone;
10 (36) Norpipanone;
11 (36.1) Para-fluorofentanyl
12 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
13 4-piperidinyl]propanamide);
14 (37) Phenadoxone;
15 (38) Phenampromide;
16 (39) Phenomorphan;
17 (40) Phenoperidine;
18 (41) Piritramide;
19 (42) Proheptazine;
20 (43) Properidine;
21 (44) Propiram;
22 (45) Racemoramide;
23 (45.1) Thiofentanyl
24 (N-phenyl-N-[1-(2-thienyl)ethyl-
25 4-piperidinyl]-propanamide);
26 (46) Tilidine;
27 (47) Trimeperidine;
28 (48) Beta-hydroxy-3-methylfentanyl (other name:
29 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
30 N-phenylpropanamide).
31 (c) Unless specifically excepted or unless listed in
32 another schedule, any of the following opium derivatives,
33 its salts, isomers and salts of isomers, whenever the
34 existence of such salts, isomers and salts of isomers is
-4- LRB9110009RCpr
1 possible within the specific chemical designation:
2 (1) Acetorphine;
3 (2) Acetyldihydrocodeine;
4 (3) Benzylmorphine;
5 (4) Codeine methylbromide;
6 (5) Codeine-N-Oxide;
7 (6) Cyprenorphine;
8 (7) Desomorphine;
9 (8) Diacetyldihydromorphine (Dihydroheroin);
10 (9) Dihydromorphine;
11 (10) Drotebanol;
12 (11) Etorphine (except hydrochloride salt);
13 (12) Heroin;
14 (13) Hydromorphinol;
15 (14) Methyldesorphine;
16 (15) Methyldihydromorphine;
17 (16) Morphine methylbromide;
18 (17) Morphine methylsulfonate;
19 (18) Morphine-N-Oxide;
20 (19) Myrophine;
21 (20) Nicocodeine;
22 (21) Nicomorphine;
23 (22) Normorphine;
24 (23) Pholcodine;
25 (24) Thebacon.
26 (d) Unless specifically excepted or unless listed in
27 another schedule, any material, compound, mixture, or
28 preparation which contains any quantity of the following
29 hallucinogenic substances, or which contains any of its
30 salts, isomers and salts of isomers, whenever the existence
31 of such salts, isomers, and salts of isomers is possible
32 within the specific chemical designation (for the purposes of
33 this paragraph only, the term "isomer" includes the optical,
34 position and geometric isomers):
-5- LRB9110009RCpr
1 (1) 3,4-methylenedioxyamphetamine
2 (alpha-methyl,3,4-methylenedioxyphenethylamine,
3 methylenedioxyamphetamine, MDA);
4 (1.1) Alpha-ethyltryptamine
5 (some trade or other names: etryptamine;
6 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
7 3-(2-aminobutyl)indole; a-ET; and AET);
8 (2) 3,4-methylenedioxymethamphetamine (MDMA);
9 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
10 (also known as: N-ethyl-alpha-methyl-
11 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
12 and MDEA);
13 (3) 3-methoxy-4,5-methylenedioxyamphetamine,
14 (MMDA);
15 (4) 3,4,5-trimethoxyamphetamine (TMA);
16 (5) (Blank);5-hydroxydimethyltryptamine
17 (Bufotenine);
18 (6) Diethyltryptamine (DET);
19 (7) Dimethyltryptamine (DMT);
20 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
21 (9) Ibogaine (some trade and other names:
22 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
23 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
24 indole; Tabernanthe iboga);
25 (10) Lysergic acid diethylamide;
26 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
27 (12) Peyote (meaning all parts of the plant
28 presently classified botanically as Lophophora williemaii
29 Lemaire, whether growing or not, the seeds thereof, any
30 extract from any part of that plant, and every compound,
31 manufacture, salts, derivative, mixture, or preparation
32 of that plant, its seeds or extracts);
33 (13) N-ethyl-3-piperidyl benzilate (JB 318);
34 (14) N-methyl-3-piperidyl benzilate;
-6- LRB9110009RCpr
1 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
2 (also known as N-hydroxy-alpha-methyl-
3 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
4 (15) Parahexyl; some trade or other names:
5 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
6 dibenzo (b,d) pyran; Synhexyl;
7 (16) Psilocybin;
8 (17) Psilocyn;
9 (18) Alpha-methyltryptamine (AMT);
10 (19) 2,5-dimethoxyamphetamine
11 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
12 (20) 4-bromo-2,5-dimethoxyamphetamine
13 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
14 4-bromo-2,5-DMA);
15 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine. Some
16 trade or other names: 2-(4-bromo-
17 2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB,
18 2CB, Nexus.
19 (21) 4-methoxyamphetamine
20 (4-methoxy-alpha-methylphenethylamine;
21 paramethoxyamphetamine; PMA);
22 (22) (Blank); Thiophene analog of phencyclidine
23 (TPCP);
24 (23) Ethylamine analog of phencyclidine. Some
25 trade or other names: N-ethyl-l-phenylcyclohexylamine,
26 (l-phenylcyclohexyl) ethylamine, N-(l-phenylcyclohexyl)
27 ethylamine, cyclohexamine, PCE;
28 (24) Pyrrolidine analog of phencyclidine. Some
29 trade or other names: l-(l-phenylcyclohexyl) pyrrolidine,
30 PCPy, PHP;
31 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
32 (26) 2,5-dimethoxy-4-ethylamphetamine
33 (another name: DOET);
34 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
-7- LRB9110009RCpr
1 (another name: TCPy);
2 (28) (Blank);3,4-methylenedioxy amphetamine;
3 (29) Thiophene analog of phencyclidine (some trade
4 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
5 2-thienyl analog of phencyclidine; TPCP; TCP);
6 (30) Bufotenine (some trade or other names:
7 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
8 3-(2-dimethylaminoethyl)-5-indolol;
9 5-hydroxy-N,N-dimethyltryptamine;
10 N,N-dimethylserotonin; mappine).
11 (e) Unless specifically excepted or unless listed in
12 another schedule, any material, compound, mixture, or
13 preparation which contains any quantity of the following
14 substances having a depressant effect on the central nervous
15 system, including its salts, isomers, and salts of isomers
16 whenever the existence of such salts, isomers, and salts of
17 isomers is possible within the specific chemical designation:
18 (1) mecloqualone;
19 (2) methaqualone; and
20 (3) gamma hydroxybutyric acid.
21 (f) Unless specifically excepted or unless listed in
22 another schedule, any material, compound, mixture, or
23 preparation which contains any quantity of the following
24 substances having a stimulant effect on the central nervous
25 system, including its salts, isomers, and salts of isomers:
26 (1) Fenethylline;
27 (2) N-ethylamphetamine;
28 (3) Aminorex (some other names:
29 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
30 4-5-dihydro-5-phenyl-2-oxazolamine) and its
31 salts, optical isomers, and salts of optical isomers;
32 (4) Methcathinone (some other names:
33 2-methylamino-1-phenylpropan-1-one;
34 Ephedrone; 2-(methylamino)-propiophenone;
-8- LRB9110009RCpr
1 alpha-(methylamino)propiophenone; N-methylcathinone;
2 methycathinone; Monomethylpropion; UR 1431) and its
3 salts, optical isomers, and salts of optical isomers;
4 (5) Chathinone (some trade or other names:
5 2-aminopropiophenone; alpha-aminopropiophenone;
6 2-amino-1-phenyl-propanone; norephedrone);
7 (6) N,N-dimethylamphetamine (also known as:
8 N,N-alpha-trimethyl-benzeneethanamine;
9 N,N-alpha-trimethylphenethylamine);
10 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
11 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine).
12 (g) Temporary listing of substances subject to emergency
13 scheduling. Any material, compound, mixture, or preparation
14 that contains any quantity of the following substances:
15 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
16 (benzylfentanyl), its optical isomers, isomers, salts,
17 and salts of isomers;
18 (2) N-[1(2-thienyl)
19 methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
20 its optical isomers, salts, and salts of isomers.
21 (Source: P.A. 89-202, eff. 10-1-95; 90-382, eff. 8-15-97.)
22 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
23 Sec. 206. (a) The controlled substances listed in this
24 Section are included in Schedule II.
25 (b) Unless specifically excepted or unless listed in
26 another schedule, any of the following substances whether
27 produced directly or indirectly by extraction from substances
28 of vegetable origin, or independently by means of chemical
29 synthesis, or by combination of extraction and chemical
30 synthesis:
31 (1) Opium and opiates, and any salt, compound,
32 derivative or preparation of opium or opiate, excluding
33 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
-9- LRB9110009RCpr
1 nalmefene, naloxone, and naltrexone, and their respective
2 salts, but including the following:
3 (i) Raw Opium;
4 (ii) Opium extracts;
5 (iii) Opium fluid extracts;
6 (iv) Powdered opium;
7 (v) Granulated opium;
8 (vi) Tincture of opium;
9 (vii) Codeine;
10 (viii) Ethylmorphine;
11 (ix) Etorphine Hydrochloride;
12 (x) Hydrocodone;
13 (xi) Hydromorphone;
14 (xii) Metopon;
15 (xiii) Morphine;
16 (xiv) Oxycodone;
17 (xv) Oxymorphone;
18 (xvi) Thebaine;
19 (xvii) Thebaine-derived butorphanol.
20 (2) Any salt, compound, isomer, derivative or
21 preparation thereof which is chemically equivalent or
22 identical with any of the substances referred to in
23 subparagraph (1), but not including the isoquinoline
24 alkaloids of opium;
25 (3) Opium poppy and poppy straw;
26 (4) Coca leaves and any salt, compound, isomer,
27 salt of an isomer, derivative, or preparation of coca
28 leaves including cocaine or ecgonine, and any salt,
29 compound, isomer, derivative, or preparation thereof
30 which is chemically equivalent or identical with any of
31 these substances, but not including decocainized coca
32 leaves or extractions of coca leaves which do not contain
33 cocaine or ecgonine (for the purpose of this paragraph,
34 the term "isomer" includes optical, positional and
-10- LRB9110009RCpr
1 geometric isomers);
2 (5) Concentrate of poppy straw (the crude extract
3 of poppy straw in either liquid, solid or powder form
4 which contains the phenanthrine alkaloids of the opium
5 poppy).
6 (c) Unless specifically excepted or unless listed in
7 another schedule any of the following opiates, including
8 their isomers, esters, ethers, salts, and salts of isomers,
9 whenever the existence of these isomers, esters, ethers and
10 salts is possible within the specific chemical designation,
11 dextrorphan excepted:
12 (1) Alfentanil;
13 (1.1) Carfentanil;
14 (2) Alphaprodine;
15 (3) Anileridine;
16 (4) Bezitramide;
17 (5) Bulk Dextropropoxyphene (non-dosage forms);
18 (6) Dihydrocodeine;
19 (7) Diphenoxylate;
20 (8) Fentanyl;
21 (9) Sufentanil;
22 (9.5) Remifentanil;
23 (10) Isomethadone;
24 (11) Levomethorphan;
25 (12) Levorphanol (Levorphan);
26 (13) Metazocine;
27 (14) Methadone;
28 (15) Methadone-Intermediate,
29 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
30 (16) Moramide-Intermediate,
31 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
32 acid;
33 (17) Pethidine (meperidine);
34 (18) Pethidine-Intermediate-A,
-11- LRB9110009RCpr
1 4-cyano-1-methyl-4-phenylpiperidine;
2 (19) Pethidine-Intermediate-B,
3 ethyl-4-phenylpiperidine-4-carboxylate;
4 (20) Pethidine-Intermediate-C,
5 1-methyl-4-phenylpiperidine-4-carboxylic acid;
6 (21) Phenazocine;
7 (22) Piminodine;
8 (23) Racemethorphan;
9 (24) Racemorphan;
10 (25) Levo-alphacetylmethadol (some other names:
11 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
12 (d) Unless specifically excepted or unless listed in
13 another schedule, any material, compound, mixture, or
14 preparation which contains any quantity of the following
15 substances having a stimulant effect on the central nervous
16 system:
17 (1) Amphetamine, its salts, optical isomers, and
18 salts of its optical isomers;
19 (2) Methamphetamine, its salts, isomers, and salts
20 of its isomers;
21 (3) Phenmetrazine and its salts;
22 (4) Methylphenidate.
23 (e) Unless specifically excepted or unless listed in
24 another schedule, any material, compound, mixture, or
25 preparation which contains any quantity of the following
26 substances having a depressant effect on the central nervous
27 system, including its salts, isomers, and salts of isomers
28 whenever the existence of such salts, isomers, and salts of
29 isomers is possible within the specific chemical designation:
30 (1) Amobarbital;
31 (2) Secobarbital;
32 (3) Pentobarbital;
33 (4) Pentazocine;
34 (5) Phencyclidine;
-12- LRB9110009RCpr
1 (6) Gluthethimide;
2 (7) (Blank). Dronabinol (synthetic) in sesame oil
3 and encapsulated in a soft gelatin capsule in a U.S. Food
4 and Drug Administration-approved drug product. Some
5 other names:
6 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-
7 pentyl-6H-dibenzo[b,d]pyran-1-ol; (-)-delta-9-(trans)-
8 tetrahydrocannabinol.
9 (f) Unless specifically excepted or unless listed in
10 another schedule, any material, compound, mixture, or
11 preparation which contains any quantity of the following
12 substances:
13 (1) Immediate precursor to amphetamine and
14 methamphetamine:
15 (i) Phenylacetone
16 Some trade or other names: phenyl-2-propanone;
17 P2P; benzyl methyl ketone; methyl benzyl ketone.
18 (2) Immediate precursors to phencyclidine:
19 (i) l-phenylcyclohexylamine;
20 (ii) l-piperidinocyclohexanecarbonitrile
21 (PCC).
22 (3) Nabilone.
23 (Source: P.A. 88-168; 89-202, eff. 10-1-95.)
24 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
25 Sec. 208. (a) The controlled substances listed in this
26 Section are included in Schedule III.
27 (b) Unless specifically excepted or unless listed in
28 another schedule, any material, compound, mixture, or
29 preparation which contains any quantity of the following
30 substances having a stimulant effect on the central nervous
31 system, including its salts, isomers (whether optical
32 position, or geometric), and salts of such isomers whenever
33 the existence of such salts, isomers, and salts of isomers is
-13- LRB9110009RCpr
1 possible within the specific chemical designation;
2 (1) Those compounds, mixtures, or preparations in
3 dosage unit form containing any stimulant substances
4 listed in Schedule II which compounds, mixtures, or
5 preparations were listed on August 25, 1971, as excepted
6 compounds under Title 21, Code of Federal Regulations,
7 Section 308.32, and any other drug of the quantitative
8 composition shown in that list for those drugs or which
9 is the same except that it contains a lesser quantity of
10 controlled substances;
11 (2) Benzphetamine;
12 (3) Chlorphentermine;
13 (4) Clortermine;
14 (5) Phendimetrazine.
15 (c) Unless specifically excepted or unless listed in
16 another schedule, any material, compound, mixture, or
17 preparation which contains any quantity of the following
18 substances having a potential for abuse associated with a
19 depressant effect on the central nervous system:
20 (1) Any compound, mixture, or preparation
21 containing amobarbital, secobarbital, pentobarbital or
22 any salt thereof and one or more other active medicinal
23 ingredients which are not listed in any schedule;
24 (2) Any suppository dosage form containing
25 amobarbital, secobarbital, pentobarbital or any salt of
26 any of these drugs and approved by the Federal Food and
27 Drug Administration for marketing only as a suppository;
28 (3) Any substance which contains any quantity of a
29 derivative of barbituric acid, or any salt thereof:
30 (4) Chlorhexadol;
31 (5) Methyprylon;
32 (6) Sulfondiethylmethane;
33 (7) Sulfonethylmethane;
34 (8) Sulfonmethane;
-14- LRB9110009RCpr
1 (9) Lysergic acid;
2 (10) Lysergic acid amide;
3 (10.1) Tiletamine or zolazepam or both, or any salt
4 of either of them.
5 Some trade or other names for a tiletamine-zolazepam
6 combination product: Telazol.
7 Some trade or other names for Tiletamine:
8 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
9 Some trade or other names for zolazepam:
10 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
11 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
12 (11) Any material, compound, mixture or preparation
13 containing not more than 12.5 milligrams of pentazocine
14 or any of its salts, per 325 milligrams of aspirin;
15 (12) Any material, compound, mixture or preparation
16 containing not more than 12.5 milligrams of pentazocine
17 or any of its salts, per 325 milligrams of acetaminophen;
18 (13) Any material, compound, mixture or preparation
19 containing not more than 50 milligrams of pentazocine or
20 any of its salts plus naloxone HCl USP 0.5 milligrams,
21 per dosage unit;
22 (14) Ketamine.
23 (d) Nalorphine.
24 (e) Unless specifically excepted or unless listed in
25 another schedule, any material, compound, mixture, or
26 preparation containing limited quantities of any of the
27 following narcotic drugs, or their salts calculated as the
28 free anhydrous base or alkaloid, as set forth below:
29 (1) not more than 1.8 grams of codeine per 100
30 milliliters or not more than 90 milligrams per dosage
31 unit, with an equal or greater quantity of an
32 isoquinoline alkaloid of opium;
33 (2) not more than 1.8 grams of codeine per 100
34 milliliters or not more than 90 milligrams per dosage
-15- LRB9110009RCpr
1 unit, with one or more active non-narcotic ingredients in
2 recognized therapeutic amounts;
3 (3) not more than 300 milligrams of
4 dihydrocodeinone per 100 milliliters or not more than 15
5 milligrams per dosage unit, with a fourfold or greater
6 quantity of an isoquinoline alkaloid of opium;
7 (4) not more than 300 milligrams of
8 dihydrocodeinone per 100 milliliters or not more than 15
9 milligrams per dosage unit, with one or more active,
10 non-narcotic ingredients in recognized therapeutic
11 amounts;
12 (5) not more than 1.8 grams of dihydrocodeine per
13 100 milliliters or not more than 90 milligrams per dosage
14 unit, with one or more active, non-narcotic ingredients
15 in recognized therapeutic amounts;
16 (6) not more than 300 milligrams of ethylmorphine
17 per 100 milliliters or not more than 15 milligrams per
18 dosage unit, with one or more active, non-narcotic
19 ingredients in recognized therapeutic amounts;
20 (7) not more than 500 milligrams of opium per 100
21 milliliters or per 100 grams, or not more than 25
22 milligrams per dosage unit, with one or more active,
23 non-narcotic ingredients in recognized therapeutic
24 amounts;
25 (8) not more than 50 milligrams of morphine per 100
26 milliliters or per 100 grams with one or more active,
27 non-narcotic ingredients in recognized therapeutic
28 amounts.
29 (f) Anabolic steroids, except the following anabolic
30 steroids that are exempt:
31 (1) Androgyn L.A.;
32 (2) Andro-Estro 90-4;
33 (3) depANDROGYN;
34 (4) DEPO-T.E.;
-16- LRB9110009RCpr
1 (5) depTESTROGEN;
2 (6) Duomone;
3 (7) DURATESTRIN;
4 (8) DUO-SPAN II;
5 (9) Estratest;
6 (10) Estratest H.S.;
7 (11) PAN ESTRA TEST;
8 (12) Premarin with Methyltestosterone;
9 (13) TEST-ESTRO Cypionates;
10 (14) Testosterone Cyp 50 Estradiol Cyp 2;
11 (15) Testosterone Cypionate-Estradiol Cypionate
12 injection; and
13 (16) Testosterone Enanthate-Estradiol Valerate
14 injection.
15 (g) Hallucenogenic substances.
16 (1) Dronabinol (synthetic) in sesame oil and
17 encapsulated in a soft gelatin capsule in a U.S. Food and
18 Drug Administration approved product. Some other names
19 for dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
20 6,6,9-trimetjyl-3-pentyl-6H-debenzo {b,d} pyran-1-ol} or
21 (-)-delta-9-(trans)-tetrahydrocannibinol.
22 (2) (Reserved).
23 (h) The Department may except by rule any compound,
24 mixture, or preparation containing any stimulant or
25 depressant substance listed in subsection (b) from the
26 application of all or any part of this Act if the compound,
27 mixture, or preparation contains one or more active medicinal
28 ingredients not having a stimulant or depressant effect on
29 the central nervous system, and if the admixtures are
30 included therein in combinations, quantity, proportion, or
31 concentration that vitiate the potential for abuse of the
32 substances which have a stimulant or depressant effect on the
33 central nervous system.
34 (Source: P.A. 89-202, eff. 10-1-95; 90-382, eff. 8-15-97.)
-17- LRB9110009RCpr
1 (720 ILCS 570/210) (from Ch. 56 1/2, par. 1210)
2 Sec. 210. (a) The controlled substances listed in this
3 Section are included in Schedule IV.
4 (b) Unless specifically excepted or unless listed in
5 another schedule, any material, compound, mixture, or
6 preparation containing limited quantities of any of the
7 following narcotic drugs, or their salts calculated as the
8 free anhydrous base or alkaloid, as set forth below:
9 (1) Not more than 1 milligram of difenoxin (DEA
10 Drug Code No. 9618) and not less than 25 micrograms of
11 atropine sulfate per dosage unit.
12 (2) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1,
13 2-diphenyl-3-methyl-2-propionoxybutane).
14 (c) Unless specifically excepted or unless listed in
15 another schedule, any material, compound, mixture, or
16 preparation which contains any quantity of the following
17 substances having a potential for abuse associated with a
18 depressant effect on the central nervous system:
19 (1) Alprazolam;
20 (2) Barbital;
21 (2.1) Bromazepam;
22 (2.2) Camazepam;
23 (3) Chloral Betaine;
24 (4) Chloral Hydrate;
25 (5) Chlordiazepoxide;
26 (5.1) Clobazam;
27 (6) Clonazepam;
28 (7) Clorazepate;
29 (7.1) Clotiazepam;
30 (7.2) Cloxazolam;
31 (7.3) Delorazepam;
32 (8) Diazepam;
33 (8.1) Estazolam;
34 (9) Ethchlorvynol;
-18- LRB9110009RCpr
1 (10) Ethinamate;
2 (10.1) Ethyl loflazepate;
3 (10.2) Fludiazepam;
4 (10.3) Flunitrazepam;
5 (11) Flurazepam;
6 (12) Halazepam;
7 (12.1) Haloxazolam;
8 (12.2) Ketazolam;
9 (12.3) Loprazolam;
10 (13) Lorazepam;
11 (13.1) Lormetazepam;
12 (14) Mebutamate;
13 (14.1) Medazepam;
14 (15) Meprobamate;
15 (16) Methohexital;
16 (17) Methylphenobarbital (Mephobarbital);
17 (17.1) Midazolam;
18 (17.2) Nimetazepam;
19 (17.3) Nitrazepam;
20 (17.4) Nordiazepam;
21 (18) Oxazepam;
22 (18.1) Oxazolam;
23 (19) Paraldehyde;
24 (20) Petrichloral;
25 (21) Phenobarbital;
26 (21.1) Pinazepam;
27 (22) Prazepam;
28 (22.1) Quazepam;
29 (23) Temazepam;
30 (23.1) Tetrazepam;
31 (24) Triazolam;
32 (24.5) Zaleplon;
33 (25) Zolpidem Zolpidam.
34 (d) Any material, compound, mixture, or preparation
-19- LRB9110009RCpr
1 which contains any quantity of the following substances,
2 including its salts, isomers (whether optical, position, or
3 geometric), and salts of such isomers, whenever the existence
4 of such salts, isomers and salts of isomers is possible:
5 (1) Fenfluramine.
6 (e) Unless specifically excepted or unless listed in
7 another schedule any material, compound, mixture, or
8 preparation which contains any quantity of the following
9 substances having a stimulant effect on the central nervous
10 system, including its salts, isomers (whether optical,
11 position or geometric), and salts of such isomers whenever
12 the existence of such salts, isomers, and salts of isomers is
13 possible within the specific chemical designation:
14 (1) Cathine ((+)-norpseudoephedrine);
15 (1.1) Diethylpropion;
16 (1.2) Fencamfamin;
17 (1.3) Fenproporex;
18 (2) Mazindol;
19 (2.1) Mefenorex;
20 (3) Phentermine;
21 (4) Pemoline (including organometallic complexes
22 and chelates thereof);
23 (5) Pipradrol;
24 (6) SPA ((-)-1-dimethylamino-1, 2-diphenylethane);.
25 (7) Modafinil;
26 (8) Sibutramine.
27 (f) Other Substances. Unless specifically excepted or
28 unless listed in another schedule, any material, compound,
29 mixture, or preparation that contains any quantity of the
30 following substance, including its salts:
31 (1) Butorphanol (including its optical isomers).
32 (g) The Department may except by rule any compound,
33 mixture, or preparation containing any depressant substance
34 listed in subsection (b) from the application of all or any
-20- LRB9110009RCpr
1 part of this Act if the compound, mixture, or preparation
2 contains one or more active medicinal ingredients not having
3 a depressant effect on the central nervous system, and if the
4 admixtures are included therein in combinations, quantity,
5 proportion, or concentration that vitiate the potential for
6 abuse of the substances which have a depressant effect on the
7 central nervous system.
8 (h) Except as otherwise provided in Section 216, any
9 material, compound, mixture, or preparation that contains any
10 quantity of the following substance having a stimulant effect
11 on the central nervous system, including its salts,
12 enantiomers (optical isomers) and salts of enantiomers
13 (optical isomers):
14 (1) Ephedrine, its salts, optical isomers and salts
15 of optical isomers.
16 (Source: P.A. 89-202, eff. 10-1-95; 90-775, eff. 1-1-99.)
17 (720 ILCS 570/214) (from Ch. 56 1/2, par. 1214)
18 Sec. 214. Excluded Substances.
19 (a) Products containing an anabolic steroid, that are
20 expressly intended for administration through implants to
21 cattle or other nonhuman species and that have been approved
22 by the Secretary of Health and Human Services for that
23 administration, and that are excluded from all schedules
24 under Section 102(41)(B)(1) of the federal Controlled
25 Substances Act (21 U.S.C. 802(41)(B)(1)) are also excluded
26 from Sections 207 and 208 of this Act.
27 (b) The non-narcotic substances excluded from all
28 schedules of the Federal Controlled Substances Act (21 U.S.C.
29 801 et seq.) pursuant to Section 1308.22 of the Code of
30 Federal regulations (21 C.F.R. 1308.22), are excluded from
31 all schedules of this Act.
32 (Source: P.A. 80-472.)
-21- LRB9110009RCpr
1 (720 ILCS 570/217 new)
2 Sec. 217. Exempt anabolic steroid products. Compounds,
3 mixtures, or preparations that contain an anabolic steroid
4 that have been exempted by the Administrator of the federal
5 Drug Enforcement Administration from application of Sections
6 302 through 309 and Sections 1002 through 1004 of the federal
7 Controlled Substances Act (21 U.S.C. 822 through 829 and 952
8 through 954) and 21 CFR 1301.13, 1301.22, and 1301.71
9 through 1301.76 are also exempt from Sections 207 and 208 of
10 this Act.
11 Section 99. Effective date. This Act takes effect upon
12 becoming law.